In this issue:
Rituximab for systemic sclerosis
Anifrolumab in patients with SLE
Risk of acute coronary syndrome in RA patients initiating biologics
Tocilizumab in patients with new-onset polymyalgia rheumatica
Risk of cancer with TNF inhibitor use
Herpes zoster risk with biologic DMARDs
Mepolizumab for eosinophilic granulomatosis with polyangiitis
New-onset vs relapsing giant cell arteritis treated with tocilizumab
Initiating biologics or intensifying conventional DMARDs in RA
Golimumab persistence in patients with axial spondyloarthritis
Please login below to download this issue (PDF)